Search

Your search keyword '"Boers, M."' showing total 1,639 results
Start Over Author "Boers, M."
1,639 results on '"Boers, M."'

1. Scandcleft Randomized Trials of Primary Surgery for Unilateral Cleft Lip and Palate: Speech Proficiency at 10 Years of Age

Author

Willadsen, E., Jørgensen, L. D., Alaluusua, S., Pedersen, N. H., Nielsen, J. B., Hölttä, E., Hide, Ø, Hayden, C., Havstam, C., Hammarström, I. L., Davies, J., Boers, M., Andersen, H. S., Aukner, R., Jackson Morris, D., Nielsen, S. F., Semb, G., Lohmander, A., and Persson, C.

Abstract

Background & Aim: To assess consonant proficiency and velopharyngeal function in 10-year-old children born with unilateral cleft lip and palate (UCLP) within the Scandcleft project. Methods & Procedures: Three parallel group, randomized, clinical trials were undertaken as an international multicentre study by nine cleft teams in five countries. Three different surgical protocols for primary palate repair (Arm B-Lip and soft palate closure at 3-4 months, hard palate closure at 36 months, Arm C-Lip closure at 3-4 months, hard and soft palate closure at 12 months, and Arm D-Lip closure at 3-4 months combined with a single-layer closure of the hard palate using a vomer flap, soft palate closure at 12 months) were tested against a common procedure (Arm A-Lip and soft palate closure at 3-4 months followed by hard palate closure at 12 months) in the total cohort of 431 children born with a non-syndromic UCLP. Speech audio and video recordings of 399 children were available and perceptually analysed. Percentage of consonants correct (PCC) from a naming test, an overall rating of velopharyngeal competence (VPC) (VPC-Rate), and a composite measure (VPC-Sum) were reported. Outcomes & Results: The mean levels of consonant proficiency (PCC score) in the trial arms were 86-92% and between 58% and 83% of the children had VPC (VPC-Sum). Only 50-73% of the participants had a consonant proficiency level with their peers. Girls performed better throughout. Long delay of the hard palate repair (Arm B) indicated lower PCC and simultaneous hard and soft palate closure higher (Arm C). However, the proportion of participants with primary VPC (not including velopharyngeal surgeries) was highest in Arm B (68%) and lowest in Arm C (47%). Conclusions & Implications: The speech outcome in terms of PCC and VPC was low across the trials. The different protocols had their pros and cons and there is no obvious evidence to recommend any of the protocols as superior. Aspects other than primary surgical method, such as time after velopharyngeal surgery, surgical experience, hearing level, language difficulties and speech therapy, need to be thoroughly reviewed for a better understanding of what has affected speech outcome at 10 years.

Published
2023
Full Text
View/download PDF

2. Studies on Reliability and Measurement Error of Measurements in Medicine – From Design to Statistics Explained for Medical Researchers

Author

Mokkink LB, Eekhout I, Boers M, van der Vleuten CP, and de Vet HC

Subjects
reliability, measurement error, classical test theory, generalizability theory, intraclass correlation coefficient, standard error of measurement, Medicine (General), R5-920
Abstract

Lidwine B Mokkink,1,2 Iris Eekhout,1– 3 Maarten Boers,1,2 Cees PM van der Vleuten,4 Henrica CW de Vet1,2 1Amsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, the Netherlands; 2Amsterdam Public Health Research Institute, Amsterdam, the Netherlands; 3Child Health, Netherlands Organisation for Applied Scientific Research, Leiden, the Netherlands; 4Department of Educational Development and Research, School of Health Professions Education, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the NetherlandsCorrespondence: Lidwine B Mokkink, Amsterdam UMC, AMC, J1B -225, Meibergdreef 9, Amsterdam, 1105 AZ, the Netherlands, Tel +31 20 44 44474, Email w.mokkink@amsterdamumc.nlAbstract: Reliability and measurement error are measurement properties that quantify the influence of specific sources of variation, such as raters, type of machine, or time, on the score of the individual measurement. Several designs can be chosen to assess reliability and measurement error of a measurement. Differences in design are due to specific choices about which sources of variation are varied over the repeated measurements in stable patients, which potential sources of variation are kept stable (ie, restricted), and about whether or not the entire measurement instrument (or measurement protocol) was repeated or only part of it. We explain how these choices determine how intraclass correlation coefficients and standard errors of measurement formulas are built for different designs by using Venn diagrams. Strategies for improving the measurement are explained, and recommendations for reporting the essentials of these studies are described. We hope that this paper will facilitate the understanding and improve the design, analysis, and reporting of future studies on reliability and measurement error of measurements.Keywords: reliability, measurement error, classical test theory, generalizability theory, intraclass correlation coefficient, standard error of measurement

Published
2023

4. POS0017 SUCCESSFUL THERAPEUTIC DRUG MONITORING BASED ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS PATIENT WITH LOW DISEASE ACTIVITY (ADDORA-LOW): A SINGLE BLIND, NON-INFERIORITY, RANDOMIZED CLINICAL TRIAL

Author

Atiqi, S., primary, Wientjes, M. H. M., additional, Leeuw, M., additional, Boekel, L., additional, Hooijberg, F., additional, Loeff, F., additional, Krieckaert, C., additional, De Vries, A., additional, Nurmohamed, M., additional, Rispens, T., additional, Boers, M., additional, Van den Bemt, B., additional, Den Broeder, A. A., additional, and Wolbink, G. J., additional

Published
2024
Full Text
View/download PDF

8. Longitudinal Speech Outcome at 5 and 10 Years in UCLP: Influence of Speech Therapy and Secondary Velopharyngeal Surgery

Author

Persson, C., Davies, J., Havstam, C., Sogaard, H., Bowden, M., Boers, M., Nielsen, J. B., Alaluusua, S., Lundeborg Hammarström, Inger, Emborg, B. K., Sand, A., Lohmander, A., Persson, C., Davies, J., Havstam, C., Sogaard, H., Bowden, M., Boers, M., Nielsen, J. B., Alaluusua, S., Lundeborg Hammarström, Inger, Emborg, B. K., Sand, A., and Lohmander, A.

Abstract

Objective: To investigate speech development of children aged 5 and 10 years with repaired unilateral cleft lip and palate (UCLP) and identify speech characteristics when speech proficiency is not at 'peer level' at 10 years. Estimate how the number of speech therapy visits are related to speech proficiency at 10 years, and what factors are predictive of whether a child's speech proficiency at 10 years is at 'peer level' or not. Design: Longitudinal complete datasets from the Scandcleft project Participants: 320 children from nine cleft palate teams in five countries, operated on with one out of four surgical methods. Interventions: Secondary velopharyngeal surgery (VP-surgery) and number of speech therapy visits (ST-visits), a proxy for speech intervention. Main Outcome Measures: 'Peer level' of percentage of consonants correct (PCC, > 91%) and the composite score of velopharyngeal competence (VPC-Sum, 0-1). Results: Speech proficiency improved, with only 23% of the participants at 'peer level' at 5 years, compared to 56% at 10 years. A poorer PCC score was the most sensitive marker for the 44% below 'peer level' at 10-year-of-age. The best predictor of 'peer level' speech proficiency at 10 years was speech proficiency at 5 years. A high number of ST-visits received did not improve the probability of achieving 'peer level' speech, and many children seemed to have received excessive amounts of ST-visits without substantial improvement. Conclusions: It is important to strive for speech at 'peer level' before age 5. Criteria for speech therapy intervention and for methods used needs to be evidence-based.

Published
2024
Full Text
View/download PDF

12. POS0225 HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY

Author

D’agostino, M. A., primary, Conaghan, P. G., additional, Gaillez, C., additional, Naredo, E., additional, Mandl, P., additional, Carron, P., additional, Šenolt, L., additional, Rosa, J., additional, López-Rodríguez, A., additional, Goyanka, P., additional, Sahoo, B. G., additional, Bao, W., additional, Schett, G., additional, and Boers, M., additional

Published
2023
Full Text
View/download PDF

14. OP0040 CHANGES IN BODY WEIGHT AND BODY COMPOSITION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AGED 65+ TREATED WITH 2-YEAR LOW-DOSE ADD-ON PREDNISOLONE IN THE RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED GLORIA TRIAL

Author

Güler-Yüksel, M., primary, Kuijper, M., additional, Bos, R., additional, Molenaar, E., additional, Emmering, J., additional, Eshuis, S., additional, Adams, H., additional, Reimann, F., additional, Boers, M., additional, and Kok, M. R., additional

Published
2023
Full Text
View/download PDF

16. POS1078 EFFECTS OF LONG-TERM LOW DOSE GLUCOCORTICOID TREATMENT FOR RHEUMATOID ARTHRITIS ON BODY WEIGHT AND BLOOD PRESSURE: A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA FROM FIVE RANDOMISED TRIALS

Author

Palmowski, A., primary, Nielsen, S. M., additional, Boyadzhieva, Z., additional, Hartman, L., additional, Oldenkott, J., additional, Svensson, B., additional, Hafström, I., additional, Wassenberg, S., additional, Choy, E., additional, Kirwan, J., additional, Christensen, R., additional, Boers, M., additional, and Buttgereit, F., additional

Published
2023
Full Text
View/download PDF

19. Auswirkungen einer zweijährigen niedrigdosierten Glucocorticoid-Therapie auf Körpergewicht und Blutdruck bei Patienten mit rheumatoider Arthritis: Eine gepoolte Analyse individueller Patientendaten von fünf randomisierten kontrollierten Studien

Author

Palmowski, A, Nielsen, SM, Christensen, R, Kirwan, J, Choy, E, Boers, M, Boyadzhieva, Z, Buttgereit, F, Hartman, L, Hafström, I, Wassenberg, S, Svensson, B, Palmowski, A, Nielsen, SM, Christensen, R, Kirwan, J, Choy, E, Boers, M, Boyadzhieva, Z, Buttgereit, F, Hartman, L, Hafström, I, Wassenberg, S, and Svensson, B

Published
2023

20. Scandcleft randomized trials of primary surgery for unilateral cleft lip and palate:Speech proficiency at 10 years of age

Author

Willadsen, Elisabeth, Jørgensen, Line Dahl, Aluusua, S, Pedersen, N.H., Nielsen, J.B., Hölttä, E., Hide, Ø, Hayden, C., Havstam, C., Hammarström, I.L., Davies, J., Boers, M., Andersen, H.S., Aukner, R., Morris, David Jackson, Nielsen, Søren Feodor, Semb, G., Lohmander, A., Persson, Christina, Willadsen, Elisabeth, Jørgensen, Line Dahl, Aluusua, S, Pedersen, N.H., Nielsen, J.B., Hölttä, E., Hide, Ø, Hayden, C., Havstam, C., Hammarström, I.L., Davies, J., Boers, M., Andersen, H.S., Aukner, R., Morris, David Jackson, Nielsen, Søren Feodor, Semb, G., Lohmander, A., and Persson, Christina

Published
2023

21. In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study

Author

Raadsen, R., primary, Agca, R., additional, Boers, M., additional, van Halm, V.P., additional, Peters, M.J.L., additional, Smulders, Y., additional, Beulens, J.W.J., additional, Blom, M.T., additional, Stehouwer, C.D.A., additional, Voskuyl, A.E., additional, Lems, W.F., additional, and Nurmohamed, M.T., additional

Published
2023
Full Text
View/download PDF

22. Scandcleft randomized trials of primary surgery for unilateral cleft lip and palate: Speech proficiency at 10 years of age

Author

Willadsen, E., primary, Jørgensen, L. D., additional, Alaluusua, S., additional, Pedersen, N. H., additional, Nielsen, J. B., additional, Hölttä, E., additional, Hide, Ø., additional, Hayden, C., additional, Havstam, C., additional, Hammarström, I. L., additional, Davies, J., additional, Boers, M., additional, Andersen, H. S., additional, Aukner, R., additional, Jackson Morris, D., additional, Nielsen, S. F., additional, Semb, G., additional, Lohmander, A., additional, and Persson, C., additional

Published
2022
Full Text
View/download PDF

23. Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial

Author

Hartman, L, primary, El Alili, M, additional, Cutolo, M, additional, Opris, D, additional, Da Silva, JAP, additional, Szekanecz, Z, additional, Buttgereit, F, additional, Masaryk, P, additional, Bos, R, additional, Kok, MR, additional, Paolino, S, additional, Coupé, VMH, additional, Lems, WF, additional, and Boers, M, additional

Published
2022
Full Text
View/download PDF

25. Diagnosis for early stage knee osteoarthritis

Author

Wang, Q.K., Runhaar, J., Kloppenburg, M., Boers, M., Bijlsma, J.W.J., Bierma-Zeinstra, S.M.A., CREDO Expert Grp, Epidemiology and Data Science, Rheumatology, AII - Inflammatory diseases, APH - Methodology, General Practice, and Orthopedics and Sports Medicine

Subjects
musculoskeletal diseases, Knee Joint, Osteoarthritis, Knee, Early diagnosis, musculoskeletal system, External validation, Cohort Studies, Radiography, Anesthesiology and Pain Medicine, Rheumatology, Internal validation, Disease Progression, Humans, Knee osteoarthritis, human activities, Probability
Abstract

Objective: To internally and externally validate our diagnostic criteria of early stage knee osteoarthritis (OA) in the CHECK and OAI cohorts. Design: We applied two previously developed diagnostic models to all knees in CHECK and OAI cohorts to calculate probabilities of early stage knee OA at baseline. Knees were categorized into three groups based on probability: 'no OA' (probability = 70%). To validate the diagnosis, we obtained OA related outcome measures at 10-year follow-up in the CHECK cohort, and at 8-9-year follow-up in the OAI cohort. We compared outcome measures between 'no OA' and 'early stage OA' knees, and between 'no OA' and 'uncertain' knees using generalized estimating equations. Results: In CHECK (n = 1042 knees) both models showed 'early stage OA' knees presented with significant and clinically relevant higher WOMAC scores, higher Kellgren & Lawrence (KL) grade, and higher rates of joint space narrowing (JSN) progression after 10 years, compared to 'no OA' knees. In OAI (n = 2937 knees) both models showed 'early stage OA' knees presented with significant and clinically relevant higher WOMAC scores, higher KL grade, and higher rates of KL and JSN progression after 8-9 years, compared to 'no OA' knees. Smaller, but still significant differences between 'uncertain' and 'no OA' knees were observed in both cohorts. Conclusions: These results support internal and external validity of the two sets of diagnostic criteria for early stage knee OA. (C) 2022 The Author(s). Published by Elsevier Inc.

Published
2022

26. Faalpadenanalyse Houtribdijk

Author

Boers, M. and Boers, M.

Abstract

Dit rapport verkent de mogelijkheden voor een Faalpadenanalyse voor de Houtribdijk tussen Enkhuizen en de Trintelhaven. Het betreft een hybride kering bestaande uit het oorspronkelijke dijklichaam met zowel aan de IJsselmeerzijde als de Markermeerzijde een aangebracht zandig profiel.

Published
2022

27. Informatiebehoefte seizoensafhankelijke hydraulische condities

Author

Boers, M. and Boers, M.

Abstract

In dit rapport worden de resultaten gepresenteerd met betrekking tot de inventarisatie van de informatiebehoefte naar seizoensafhankelijke hydraulische condities. Daarvoor zijn zeven interviews gehouden met medewerkers van Rijkswaterstaat, Waterschappen en de STOWA.

Published
2022

29. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.

Author

Ruwaard, J, L' Ami, MJ, Kneepkens, EL, Krieckaert, CLM, Nurmohamed, MT, Hooijberg, F, van Kuijk, AWR, van Denderen, JC, Burgemeister, L, Rispens, T, Boers, M, and Wolbink, GJ

Subjects
ANKYLOSING spondylitis, PSORIATIC arthritis, RHEUMATOID arthritis, RANDOMIZED controlled trials, ETANERCEPT
Abstract

The majority of patients with a rheumatic disease treated with etanercept may be overexposed. Data regarding etanercept tapering are scarce, particularly in psoriatic arthritis (PsA) and ankylosing spondylitis (AS). We compared extending the dose interval to continuation of the standard dose and studied the success rate of etanercept discontinuation. Etanercept concentrations were measured throughout the study. 160 patients with rheumatoid arthritis (RA), PsA, or AS with sustained minimal disease activity (MDA) were enrolled in this 18-month, open-label, randomized controlled trial. The intervention group doubled the dosing interval at baseline and discontinued etanercept 6 months later. The control group continued the standard dose for 6 months and doubled the dosing-interval thereafter. The primary outcome was the proportion of patients maintaining MDA at 6 month follow-up. At 6 months, MDA status was maintained in 47 patients (63%) in the intervention group and 56 (74%) in the control group (p = 0.15), with comparable results in all rheumatic diseases. And median etanercept concentrations decreased from 1.50 µg/mL (interquartile range 1.06– 2.65) to 0.46 µg/mL (0.28–0.92). In total, 40% discontinued etanercept successfully with maintained MDA for at least 6 months. Etanercept tapering can be done without losing efficacy in RA, PsA, and AS patients in sustained MDA. A substantial proportion of patients could stop etanercept for at least 6 months. In many patients, low drug concentrations proved sufficient to control disease activity. However, the risk of minor and major flares is substantial, even in patients continuing standard dosing. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. AB0166 PROTOCOL VIOLATIONS IN AN OPEN, RANDOMIZED, TRIAL IN EARLY RA PATIENTS: POTENTIAL IMPACT OF SHARED DECISION MAKING

Author

Hartman, L., primary, Rasch, L. A., additional, Turk, S. A., additional, ter Wee, M., additional, Kerstens, P. J. S. M., additional, van der Laken, C. J., additional, Nurmohamed, M. T., additional, van Schaardenburg, D., additional, van Tuyl, L. H. D., additional, Voskuyl, A., additional, Boers, M., additional, and Lems, W., additional

Published
2022
Full Text
View/download PDF

33. OP0270 TAPERING OF LONG-TERM, LOW-DOSE GLUCOCORTICOIDS IN SENIOR RHEUMATOID ARTHRITIS PATIENTS: FOLLOW-UP OF THE PRAGMATIC, MULTICENTRE, PLACEBO-CONTROLLED GLORIA TRIAL

Author

Almayali, A., primary, Boers, M., additional, Hartman, L., additional, Opris-Belinski, D., additional, Bos, R., additional, Kok, M. R., additional, da Silva, J. A. P., additional, Griep, E. N., additional, Klaasen, R., additional, Allaart, C., additional, Baudoin, P., additional, Raterman, H., additional, Szekanecz, Z., additional, Buttgereit, F., additional, Masaryk, P., additional, Lems, W., additional, Cutolo, M., additional, and Ter Wee, M., additional

Published
2022
Full Text
View/download PDF

34. OP0260 RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO csDMARDs: DATA FROM THE ULTIMATE TRIAL

Author

D’Agostino, M. A., primary, Boers, M., additional, Gaillez, C., additional, Gamez, C., additional, Ventura, L., additional, Rosa, J., additional, Padovano, I., additional, Mandl, P., additional, Kleyer, A., additional, Bakewell, C., additional, Bao, W., additional, Goyanka, P., additional, Conaghan, P. G., additional, and Schett, G., additional

Published
2022
Full Text
View/download PDF

35. OP0178 COVID-19 BREAKTHROUGH INFECTIONS IN VACCINATED PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES AND CONTROLS – DATA FROM TWO PROSPECTIVE COHORT STUDIES

Author

Boekel, L., primary, Stalman, E., additional, Wieske, L., additional, Hooijberg, F., additional, Besten, Y., additional, Leeuw, M., additional, Atiqi, S., additional, Kummer, L., additional, van Dam, K., additional, Steenhuis, M., additional, van Kempen, Z., additional, Killestein, J., additional, Lems, W., additional, Tas, S., additional, van Vollenhoven, R., additional, Nurmohamed, M., additional, Boers, M., additional, van Ham, M., additional, Rispens, T., additional, Kuijpers, T., additional, Eftimov, F., additional, and Wolbink, G. J., additional

Published
2022
Full Text
View/download PDF

37. OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL

Author

D’Agostino, M. A., primary, Boers, M., additional, Schett, G., additional, Conaghan, P. G., additional, Naredo, E., additional, Mandl, P., additional, Carron, P., additional, Backhaus, M., additional, López-Rodríguez, A., additional, Hanova, P., additional, Goyanka, P., additional, Sahoo, B. G., additional, Gaillez, C., additional, and Bao, W., additional

Published
2022
Full Text
View/download PDF

38. POS0971 THE RELATIONSHIP OF AXIAL [18F]FLUORIDE UPTAKE ON PET-CT TO ANATOMICAL CHANGES ON MRI AND X-RAY IN CLINICALLY ACTIVE ANKYLOSING SPONDYLITIS PATIENTS

Author

De Jongh, J., primary, Pouw-Verweij, N., additional, Zwezerijnen, G. C. J., additional, Van Denderen, J. C., additional, Van der Horst-Bruinsma, I., additional, Bot, J., additional, Boden, B. J. H., additional, Hemke, R., additional, Smithuis, F. F., additional, Voskuyl, A., additional, Boers, M., additional, Yaqub, M., additional, and Van der Laken, C. J., additional

Published
2022
Full Text
View/download PDF

39. POS1402 COST-EFFECTIVENESS AND COST-UTILITY OF ADD-ON, LOW-DOSE PREDNISOLONE IN RA PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO-CONTROLLED GLORIA TRIAL

Author

Hartman, L., primary, El Alili, M., additional, Cutolo, M., additional, Opris-Belinski, D., additional, Da Silva, J. A. P., additional, Szekanecz, Z., additional, Buttgereit, F., additional, Masaryk, P., additional, Bos, R., additional, Kok, M. R., additional, Paolino, S., additional, Coupé, V. M. H., additional, Lems, W., additional, and Boers, M., additional

Published
2022
Full Text
View/download PDF

40. POS1410 DEVELOPMENT OF PREDICTION MODELS FOR SENIOR PATIENTS WITH RHEUMATOID ARTHRITIS AND COMORBIDITIES TREATED WITH CHRONIC LOW-DOSE GLUCOCORTICOIDS IN THE GLORIA TRIAL

Author

Hartman, L., primary, Da Silva, J. A. P., additional, Buttgereit, F., additional, Cutolo, M., additional, Opris-Belinski, D., additional, Szekanecz, Z., additional, Masaryk, P., additional, Voshaar, M., additional, Heijmans, M. W., additional, Lems, W., additional, Van der Heijde, D., additional, and Boers, M., additional

Published
2022
Full Text
View/download PDF

41. OP0263 FAVORABLE BALANCE OF BENEFIT AND HARM OF LONG-TERM, LOW-DOSE PREDNISOLONE ADDED TO STANDARD TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO- CONTROLLED GLORIA TRIAL

Author

Boers, M., primary, Hartman, L., additional, Opris-Belinski, D., additional, Bos, R., additional, Kok, M. R., additional, da Silva, J. A. P., additional, Griep, E. N., additional, Klaasen, R., additional, Allaart, C., additional, Baudoin, P., additional, Raterman, H., additional, Szekanecz, Z., additional, Buttgereit, F., additional, Masaryk, P., additional, Klausch, T., additional, Paolino, S., additional, Schilder, A. M., additional, Lems, W., additional, and Cutolo, M., additional

Published
2022
Full Text
View/download PDF

44. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

Author

Ruwaard, J, primary, L’ Ami, MJ, additional, Kneepkens, EL, additional, Krieckaert, CLM, additional, Nurmohamed, MT, additional, Hooijberg, F, additional, van Kuijk, AWR, additional, van Denderen, JC, additional, Burgemeister, L, additional, Rispens, T, additional, Boers, M, additional, and Wolbink, GJ, additional

Published
2022
Full Text
View/download PDF

45. Towards developing diagnostic criteria for early knee osteoarthritis: data from the CHECK study

Author

Runhaar, J., Kloppenburg, M., Boers, M., Bijlsma, J.W.J., Bierma-Zeinstra, S.M.A., CREDO Expert Grp, Epidemiology and Data Science, Rheumatology, APH - Methodology, General Practice, and Orthopedics and Sports Medicine

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Knee Joint, Radiography, Physical examination, Osteoarthritis, Severity of Illness Index, knee osteoarthritis, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Medicine, Humans, Pharmacology (medical), Medical history, Medical diagnosis, AcademicSubjects/MED00360, Aged, 030203 arthritis & rheumatology, medicine.diagnostic_test, business.industry, Medical record, Gold standard, Clinical Science, Middle Aged, Osteoarthritis, Knee, medicine.disease, 030104 developmental biology, Knee pain, Early Diagnosis, diagnostic criteria, Physical therapy, Disease Progression, Female, medicine.symptom, business, expert diagnosis
Abstract

Objectives There is a general consensus that a shift in focus towards early diagnosis and treatment of knee OA is warranted. However, there are no validated and widely accepted diagnostic criteria for early knee OA available. The current study aimed to take the first steps towards developing diagnostic criteria for early knee OA. Methods Data of 761 individuals with 1185 symptomatic knees at baseline were selected from the CHECK study. For CHECK, individuals with pain/stiffness of the knee, aged 45–65 years, who had no prior consultation or a first consultation with the general practitioner for these symptoms in the past 6 months were recruited and followed for 10 years. A group of 36 experts (17 general practitioners and 19 secondary care physicians) evaluated the medical records in pairs to diagnose the presence of clinically relevant knee OA 5–10 years after enrolment. A backward selection methods was used to create predictive models based on pre-defined baseline factors from history taking, physical examination, radiography and blood testing, using the experts’ diagnoses as gold standard outcome. Results Prevalence of clinically relevant knee OA during follow-up was 37%. Created models contained 7–11 baseline factors and obtained an area under the curve between 0.746 (0.002) and 0.764 (0.002). Conclusion The obtained diagnostic models for early knee OA had ‘fair’ predictive ability in individuals presenting with knee pain in primary care. Further modelling and validation of the identified predictive factors is required to obtain clinically feasible and relevant diagnostic criteria for early knee OA.

Published
2020

46. Data Visualization for Biomedical Scientists: Creating Tables and Graphs That Work

Author

Boers, M, Epidemiology and Data Science, and APH - Methodology

Abstract

Good research can only be impactful if the message gets across. Tables and graphs are essential for scientific communication, but those we see rarely meet their full design potential. To date, progress in data visualization has not resulted in specific guidance for biomedical science. This book aims to fill these gaps, using a hands-on, stepwise approach to make scientific tables and graphs that work. From design principles and basic forms to complex matrix graphs, high-impact publications and presentations. Richly illustrated and documented, its broad scope should appeal to both young and experienced investigators. Additional content is available at: www.vuuniversitypress.com/datavisualization

Published
2022

50. Réponse échographique et clinique de l’atteinte des synovites chez les patients atteints de rhumatisme psoriasique traités par sécukinumab : résultats de l’étude ULTIMATE

Author

D’Agostino, M.A., primary, Conaghan, P., additional, Schett, G., additional, Mandl, P., additional, Naredo, E., additional, Van den Bosch, F., additional, Burgos-Vargas, R., additional, Duggan, A.M., additional, Goyanka, P., additional, Gaillez, C., additional, and Boers, M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results